Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Effects of Different Doses of Caffeine on Physical and Cognitive Performance in Female Handball Players

24 de abril de 2026 atualizado por: Ulaş Can YILDIRIM, Sinop University

Dose-Dependent Effects of Acute Caffeine Ingestion on Physical and Cognitive Performance in Female Handball Players: A Randomized, Double-Blind, Placebo-Controlled Crossover Study

This study investigates how different doses of caffeine affect physical and cognitive performance in female handball players. Caffeine is widely used as a performance-enhancing substance, but its effects may vary depending on the type of performance and the dose consumed.

In this randomized, double-blind, placebo-controlled crossover study, participants complete three experimental conditions: placebo, low-dose caffeine (3 mg/kg), and moderate-dose caffeine (6 mg/kg). Each participant receives all conditions in a randomized order, with sufficient time between sessions to avoid carryover effects.

The study evaluates three main performance domains relevant to team sports. Physical performance is assessed using an intermittent running test. Cognitive performance is measured using a reaction time task that evaluates attention and inhibitory control. In addition, a throwing test is used to assess sport-specific motor performance.

The main objective is to determine whether caffeine produces dose-dependent improvements and whether these effects differ across physical, cognitive, and technical performance domains. The findings aim to provide practical insights for athletes and coaches regarding optimal caffeine use in team sport settings.

Visão geral do estudo

Descrição detalhada

Caffeine is one of the most widely consumed ergogenic aids in sport, known to influence both physiological and cognitive processes primarily through antagonism of adenosine receptors. Although its beneficial effects on endurance performance and alertness are well established, evidence regarding its effects on cognitive control and sport-specific technical skills remains inconsistent, particularly in team sport settings where multiple performance domains interact.

Team sports such as handball require the integration of intermittent high-intensity physical efforts, rapid decision-making, and precise motor execution. These components are not independent; instead, they compete for shared neurocognitive resources, especially under conditions of fatigue. As a result, interventions such as caffeine supplementation may exert domain-specific effects rather than uniform improvements across all aspects of performance.

Despite extensive research on caffeine, most studies have examined either physical or cognitive outcomes in isolation. Furthermore, dose-response relationships remain unclear, with previous findings suggesting that lower doses may be sufficient to enhance physical performance, whereas cognitive outcomes may require higher levels of stimulation. However, limited evidence exists on whether these dose-dependent effects are maintained when multiple performance domains are assessed within the same experimental framework.

The present study addresses this gap by simultaneously evaluating physical, cognitive, and sport-specific motor performance following different doses of caffeine in female handball players. A randomized, double-blind, placebo-controlled crossover design is used to minimize inter-individual variability and improve internal validity. Participants complete three experimental conditions (placebo, low-dose caffeine, and moderate-dose caffeine), each separated by an adequate washout period to reduce potential carryover effects.

The protocol includes standardized procedures to control for confounding factors such as time of day, environmental conditions, and prior physical activity. Testing sessions follow a fixed sequence, beginning with cognitive assessment, followed by a sport-specific throwing task, and concluding with an intermittent running test. This structure is designed to reflect the multi-component demands of team sport performance while maintaining methodological control.

The primary objective is to determine whether caffeine produces dose-dependent effects across different performance domains. Specifically, the study examines whether physical performance improvements occur at lower doses, whether cognitive performance shows greater sensitivity to higher doses, and whether technical motor performance responds differently to caffeine ingestion. By integrating these domains within a single experimental design, the study aims to provide a more ecologically valid understanding of caffeine's ergogenic effects in team sport contexts.

The findings are expected to contribute to evidence-based recommendations for caffeine use in athletes, emphasizing the importance of aligning supplementation strategies with specific performance goals rather than assuming uniform benefits across all domains.

Tipo de estudo

Intervencional

Inscrição (Real)

20

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Female handball players
  • Regular participation in competitive handball training
  • Minimum of 3 years of handball training experience
  • Free from musculoskeletal injury within the past 6 months

Exclusion Criteria:

  • Known caffeine sensitivity or allergy
  • Use of medications or supplements that may affect physical or cognitive performance
  • Presence of cardiovascular disease
  • Presence of metabolic disorders

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador de Placebo: Placebo Condition
Participants receive placebo capsules prior to testing in a randomized
Ingestion of identical capsules containing polydextrose with no active ingredient, administered 60 minutes prior to testing.
Experimental: Low-Dose Caffeine
Participants receive 3 mg/kg caffeine prior to testing in a randomized
Acute ingestion of caffeine at a dose of 3 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.
Experimental: Moderate-Dose Caffeine
Participants receive 6 mg/kg caffeine prior to testing in a randomized
Acute ingestion of caffeine at a dose of 6 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Flanker Task Reaction Time
Prazo: During each experimental session (60 minutes after supplementation)
Mean reaction time (ms) during correct trials in the Simplified Eriksen Flanker task, used to assess cognitive processing speed.
During each experimental session (60 minutes after supplementation)
Yo-Yo Intermittent Recovery Test Level 1 Distance
Prazo: During each experimental session (60 minutes after supplementation)
Total distance covered during the Yo-Yo Intermittent Recovery Test Level 1, used to assess intermittent running performance.
During each experimental session (60 minutes after supplementation)
Throwing Velocity
Prazo: During each experimental session (60 minutes after supplementation)
Mean ball velocity (km/h) measured during a standardized handball throwing test.
During each experimental session (60 minutes after supplementation)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Flanker Task Accuracy
Prazo: During each experimental session (60 minutes after supplementation)
Percentage of correct responses in the Simplified Eriksen Flanker task.
During each experimental session (60 minutes after supplementation)
Flanker Effect
Prazo: During each experimental session (60 minutes after supplementation)
Difference in reaction time between incongruent and congruent trials in the Flanker task.
During each experimental session (60 minutes after supplementation)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

25 de janeiro de 2026

Conclusão Primária (Real)

10 de março de 2026

Conclusão do estudo (Real)

20 de março de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

24 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

24 de abril de 2026

Primeira postagem (Real)

1 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de maio de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

24 de abril de 2026

Última verificação

1 de abril de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

At the time of registration, a decision regarding sharing individual participant data (IPD) has not yet been finalized. The study dataset is currently being prepared for publication and institutional archiving. Future data sharing will be considered after publication, taking into account institutional policies, ethical approvals, and participant confidentiality requirements. If appropriate, de-identified data underlying the published results may be made available upon reasonable request.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever